FDA official still wary about MS drug
Duluth News Tribune - Duluth,MN,USA
WASHINGTON - Dozens of multiple sclerosis patients asked federal health advisers Tuesday to let them decide whether to take Tysabri, a promising drug that was ...

FDA official still wary about MS drug
USA Today - USA
WASHINGTON (AP) — Some patients who take a promising multiple sclerosis drug will likely die of a rare brain infection if the medicine, Tysabri, is allowed ...

Biogen, Elan Propose Measures to Control Tysabri Risk (Update4)
Bloomberg - USA
and Elan Corp., seeking to resume US sales of their multiple sclerosis drug Tysabri, proposed to restrict the treatment's use to reduce the risk patients will ...
See all stories on this topic

UPDATE 1-Patients urge return of Biogen MS drug
Reuters - USA
... marketing partner Elan Corp (ELN.N: Quote, Profile, Research) (ELN.I: Quote, Profile, Research) voluntarily suspended sales of the drug, Tysabri, in February ...
See all stories on this topic

Controversial drug to undergo gov't hearings
CTV.ca - Canada
Tysabri, produced by Cambridge, Mass-based Biogen IDEC and Elan Pharmaceuticals of Ireland, was pulled off the market a year ago after three patients developed ...

Teva Shares Already Pricing In Tysabri Return
Forbes - USA
The firm reiterated an "outperform" rating on Teva (nasdaq: TEVA - news - people ) and said current prices anticipate a re-launch of Tysabri, a multiple ...
See all stories on this topic

US close: Stocks mixed as techs fall
ShareCast - London,UK
... Biotech firms Biogen and Elan will find out the fate of their suspended drug Tysabri as the US Food and Drug Administration (FDA) advisory committee meets to ...
See all stories on this topic

Mixed fortunes for exploration companies on falling ISEQ
Ireland Online - Dublin,Ireland
... Elan gained 35c (3.3%) to €10.95 on the day that the US Food and Drug Administration will hold a public meeting on its multiple sclerosis drug Tysabri. ...